Objective Tiotropium is a long-acting muscarinic antagonist approved for maintenance
treatment of asthma in children, adolescents, and adults in the United States, and …

Asthma is a chronic disease of airway inflammation with a large global burden. Despite
established, guideline‐based stepwise therapy, a significant proportion of patients remain …

Introduction: Tiotropium, a once-daily long-acting anticholinergic bronchodilator, has
recently been approved for use in the treatment of asthma in a number of countries …

Severe and poorly controlled asthma still accounts for a great portion of the patients affected.
Disease control and future risk management have been identified by international …

Asthma is a heterogeneous disease characterized by airway inflammation resulting from
complex interactions between multiple hosts as well as environmental factors. As a chronic …

Asthma is among the most common chronic diseases worldwide; however, despite
progresses in the understanding of the patho-physiological mechanisms and advances in …

Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory
effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy …

BACKGROUND The role of tiotropium for the treatment of asthma has not yet been clearly
defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium …

Background Asthma is a major cause of morbidity in children, despite the availability of
various treatments. In adults, tiotropium—a long-acting muscarinic antagonist—as add-on …

BACKGROUND: Some patients with severe asthma remain symptomatic and obstructed
despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic …